3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
100
Nivolumab
69
Cyclophosphamide
67
Ipilimumab
66
fludarabine
34
aldesleukin
29
fludarabine phosphate
28
Vemurafenib
28
Interleukin-2
26
trametinib
20
Biopsy
20
dabrafenib
17
Radiotherapy
16
Temozolomide
15
Cisplatin
15
Magnetic Resonance Spectroscopy
14
Gemcitabine
14
Filgrastim
14
atezolizumab
13
Specimen Handling
13
Carboplatin
13
CTLA-4 Antigen
13
spartalizumab
12
romidepsin
12
Paclitaxel
12
Bortezomib
11
poly ICLC
10
cobimetinib
10
Peripheral Blood Stem Cell Transplantation
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
High-Intensity Focused Ultrasound Ablation
×
Dermatologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled